Allison [7] discovered that the blockade of CTLA-4 with monoclonal antibodies restricted the binding of CTLA-4 to its ligands and increased anti-tumor immune responses with tumor rejection [7,10,11]. The gene discussed is CTLA4; the disease is neoplasm.